Skip to search formSkip to main contentSkip to account menu

telavancin

Known as: Telavancina, Telavancinum, (1S,2R,18R,19R,22S,25R,28R,40S)-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-{[(2S,3R,4S,5S,6R)-3-{[(2S,4S,5S,6S)-4-{[2-(decylamino)ethyl]amino}-5-hydroxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}-2 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (2)

AminoglycosidesAnti-Bacterial Agents
Bacterial InfectionsLipoglycopeptides [Chemical/Ingredient]telavancin 250 MG Injection [Vibativ]telavancin hydrochloride

Narrower (1)

TD 6424

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Population Pharmacokinetics of Telavancin in Healthy Subjects and Patients with Infections
ABSTRACT A population pharmacokinetic model of telavancin, a lipoglycopeptide antibiotic, was developed and used to identify… 
2010
2010
Fresh from the biologic pipeline—2009
Human antibodies take center stage, as they pile up in the list of approved biologics in 2009. Cormac Sheridan reports. 
2010
2010
Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia.
OBJECTIVES The antimicrobial activity of telavancin against 2279 clinical Gram-positive cocci obtained from patients with… 
2010
2010
Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
OBJECTIVES Infections caused by heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) are associated with high… 
Review
2009
Review
2009
Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria.
2009
2009
Activity of Telavancin against Staphylococcus aureus Strains with Various Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations
ABSTRACT We investigated the activity of telavancin, a novel lipoglycopeptide, alone and combined with gentamicin or rifampin… 
Highly Cited
2008
Highly Cited
2008
In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
OBJECTIVES Telavancin is a novel semi-synthetic lipoglycopeptide currently in late-stage clinical development for the treatment… 
2007
2007
Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureus
ABSTRACT The efficacy of telavancin, a novel lipoglycopeptide, was evaluated in experimental endocarditis in rabbits using two… 
2007
2007
Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus.
OBJECTIVES To assess the efficacy of telavancin, a rapidly bactericidal lipoglycopeptide, and three comparator agents in a murine… 
Highly Cited
2006
Highly Cited
2006
Tissue Penetration of Telavancin after Intravenous Administration in Healthy Subjects
ABSTRACT The pharmacokinetic disposition of telavancin administered 7.5 mg/kg of body weight every 24 h was determined in plasma… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)